IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
Kevin C ConlonE Lake PotterStefania PittalugaChyi-Chia Richard LeeMilos D MiljkovicThomas A FleisherSigrid DuboisBonita R BryantMichael PetrusLiyanage P PereraJennifer HsuWilliam Douglas FiggCody J PeerJoanna H ShihJason L YovandichStephen P CreekmoreMario RoedererThomas A WaldmannPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This phase I trial identified the MTD for CIV rhIL15 and defined a treatment regimen that produced significant expansions of CD8+ T and NK effector cells in circulation and tumor deposits. This regimen has identified several biological features, including dramatic increases in numbers of NK cells, supporting trials of IL15 with anticancer mAbs to increase antibody-dependent cell-mediated cytotoxicity and anticancer efficacy.
Keyphrases
- nk cells
- phase iii
- study protocol
- induced apoptosis
- phase ii
- clinical trial
- single cell
- cell cycle arrest
- high glucose
- low dose
- cell therapy
- diabetic rats
- dendritic cells
- high dose
- regulatory t cells
- randomized controlled trial
- drug induced
- stem cells
- combination therapy
- cell death
- signaling pathway
- immune response
- health insurance
- affordable care act
- smoking cessation
- pi k akt